Prosecution Insights
Last updated: April 19, 2026
Application No. 18/509,310

LAUNDERABLE BACTERICIDAL AND VIRUCIDAL FABRIC FINISH

Non-Final OA §DP
Filed
Nov 15, 2023
Examiner
LAZARO, DOMINIC
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nano And Advanced Materials Institute Limited
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
3y 2m
To Grant
95%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
400 granted / 639 resolved
+2.6% vs TC avg
Strong +32% interview lift
Without
With
+32.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
46 currently pending
Career history
685
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
44.7%
+4.7% vs TC avg
§102
9.8%
-30.2% vs TC avg
§112
23.7%
-16.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 639 resolved cases

Office Action

§DP
DETAILED ACTION Status of Claims Claims 1-14 are currently pending. Claims 1-4 and 13 are currently under consideration and are the subject of this Office Action. This is the first Office Action on the merits of the claims. Non-elected claims 5-12 and 14 are withdrawn from consideration. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Office Action: Non-Final. Election/Restrictions Applicant’s election of the claims of Group I (claims 1-4 and 13) in the response filed on January 19, 2026 (to the December 31, 2025 Requirement for Restriction) is acknowledged. In response to applicant’s election, the claims of Group II (claims 5-10 and 14) and Group III (claims 11-12) are withdrawn from further consideration pursuant to 37 C.F.R. § 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant has elected the claims of Group I with traverse. The traverse is based on applicant’s argument: […]. It is respectfully submitted that the search for these sets of claims substantially overlaps. Further, the issues regarding patentability are the same for these sets of claims. Therefore, it is requested that the restriction requirement be withdrawn. (01/19/2026 Remarks, p. 1, par. 1). In response: , it is noted that since the claims drawn to the instant kit are not patentable, as discussed below, restriction is still deemed proper. Further, it is noted that Groups I, II and III, as originally restricted 12/31/2025 Office action, are in separate areas of classification (i.e., Group I, the kit in CPC D06B 21/00, Group II, a method of preparing in CPC A01N 37/20, and Group III, a fabric in CPC A01P 1/00), wherein the separate classification provides for the inventions of Groups I and II as being distinct, and whereby art that would read on Group I, would not read on claims Groups II or III, and vice versa. Also in the response dated January 19, 2026, applicant elected the following species: “(a) compound of formula I,” and identified “all of the claims correspond[ing] to the elected species.” Accordingly, the January 19, 2026 Requirement for Restriction is made FINAL, and claims 1-4 and 13 are examined as follows. Claim Rejections - Nonstatutory Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b). Claims 1-4 and 13 are rejected on the ground of nonstatutory double patenting over claims 1-4 and 13 of US Patent 11,856,953 to O et al., hereinafter “‘953 Patent", matured from copending Application No. 17/692,123. Although the conflicting claims are not identical, they are not patentably distinct because the instant claims as well as the copending claims are drawn to a kit for a launderable bactericidal and virucidal fabric finish formulation for home application comprising a first component having a bactericidal and virucidal agent; a second component comprising one or more crosslinkers, and/or one or more catalysts; and a third component comprising one or more transition metal salts. Claim 1 is anticipated by claim 1 of the ‘953 Patent. It is noted that claim 1 is broader is scope for drawn to a “kit for a launderable bactericidal and virucidal fabric finish formulation for home application comprising,” whereas claim 1 of the ‘953 Patent is narrower in scope being drawn to “[a] kit for a launderable bactericidal and virucidal fabric finish formulation for home laundry.” Claim 2 is anticipated by claim 2 of the ‘953 Patent. Claim 3 is anticipated by claim 3 of the ‘953 Patent. Claim 4 is anticipated by claim 4 of the ‘953 Patent. Claim 13 is obvious over claims 1 and 13 of the ‘953 Patent. See MPEP § 2123 [R-5] regarding the obviousness of rearranging a reference according to the teachings of that same reference. Conclusion Claims 1-4 and 13 are rejected. No claims are allowed. CN 110 904 679 A by Ge et al., Publ. Mar. 24, 2020, as evidenced by English language translation of CN 110 904 679 A (on 04/24/2024 IDS) is noted as a reference of interest. Any inquiry concerning this communication or earlier communications from the examiner should be directed to DOMINIC LAZARO whose telephone number is (571)272-2845. The examiner can normally be reached on Monday through Friday, 8:30am to 5:00pm EST; alternating Fridays out. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, BETHANY BARHAM can be reached on (571)272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DOMINIC LAZARO/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Nov 15, 2023
Application Filed
Feb 21, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594234
NOVEL USE OF AN EPILOBIUM FLEISCHERI EXTRACT
2y 5m to grant Granted Apr 07, 2026
Patent 12589080
Enhanced Two-Stage Microparticle-Based Localized Therapeutic Delivery System
2y 5m to grant Granted Mar 31, 2026
Patent 12582658
THERAPEUTIC CONSTRUCTS FOR CO-DELIVERY OF ANTI-CANCER AGENT(S) AND IMMUNE CHECKPOINT INHIBITOR(S)
2y 5m to grant Granted Mar 24, 2026
Patent 12558391
Sustained Release Formulation Containing Aspalathus linearis Extract
2y 5m to grant Granted Feb 24, 2026
Patent 12558460
POROUS INORGANIC PARTICLE, AND COMPOSITE FILLER, PRODUCT USING THE SAME
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
95%
With Interview (+32.3%)
3y 2m
Median Time to Grant
Low
PTA Risk
Based on 639 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month